Clinical Trial Update: Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating adoptive regulatory T cells to suppress acute graft-versus-host disease after umbilical cord blood stem cell transplantat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Burkitt Lymphoma

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Lymphoblastic Leukemia, Burkitt Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2020-07-24